Walnut Creek, CA, United States of America

Dale Ando

USPTO Granted Patents = 12 (Patent Applications = 1)

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 151(Granted Patents)

Location History:

Walnut Creek, CA (US) (2007 - 2021)
Richmond, CA (US) (2013 - 2024)
Brisbane, CA (US) (2024)

Company Filing History:

6 out of 160

Sangamo Biosciences, Inc.

patents

3 out of 145

Sangamo Therapeutics, Inc.

Biosante Pharmaceuticals, Inc.

patents

6. 1 out of 3,682

The Johns Hopkins University

patents

where one patent can have more than one assignee

Years Active: 2007-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11884930 - Method of inactivating a glucocorticoid receptor gene in an isolated cell (2024-01-30),

2. 11857641 - Method for the treatment of mucopolysaccharidosis type I (2024-01-02),

3. 11648267 - Methods and compositions for gene inactivation (2023-05-16),

4. 10907175 - Isolated human cell with an inactivated glucocorticoid receptor gene (2021-02-02),

5. 9434776 - Methods and compositions for gene inactivation (2016-09-06),

6. 9217026 - Method of inactivating a glucocorticoid receptor gene in an isolated cell (2015-12-22),

7. 8569253 - Methods and compositions for gene inactivation (2013-10-29),

8. 8524221 - Methods and compositions for gene inactivation (2013-09-03),

9. 7951925 - Methods and compositions for gene inactivation (2011-05-31),

10. 7645587 - Cancer-associated antigens and methods of their identification and use (2010-01-12),

11. 7226606 - Cancer-associated antigens and methods of their identification and use (2007-06-05),

12. 7217421 - Cancer-associated antigens and methods of their identification and use (2007-05-15),

Title: The Innovative Contributions of Dale Ando

Introduction

Dale Ando is a prominent inventor based in Walnut Creek, California, known for his significant contributions to the field of biotechnology. With a total of 12 patents to his name, Ando has made remarkable advancements in therapeutic applications, particularly in the treatment of genetic disorders.

Latest Patents

Among his latest patents is a method of inactivating a glucocorticoid receptor gene in an isolated cell. This invention discloses methods and compositions for the inactivation of the human glucocorticoid receptor (GR) gene through targeted cleavage of genomic DNA encoding the GR. Such methods are particularly useful in therapeutic applications that require the retention of immune function during glucocorticoid treatment. Another notable patent is for the treatment of mucopolysaccharidosis type I (MPS I). This patent describes methods and compositions for treating MPS I by administering a composition comprising an iduronidase (IDUA) polynucleotide. The method aims to reduce, delay, and/or eliminate the need for additional treatment procedures, as well as the onset, progression, and severity of symptoms in subjects with MPS I.

Career Highlights

Dale Ando has had a distinguished career, working with leading companies in the biotechnology sector. He has been associated with Sangamo Biosciences, Inc. and Sangamo Therapeutics, Inc., where he has contributed to groundbreaking research and development efforts.

Collaborations

Throughout his career, Ando has collaborated with notable professionals in the field, including Michael C. Holmes and Gary Ka Leong Lee. These collaborations have further enhanced his innovative work and contributed to the advancement of therapeutic solutions.

Conclusion

Dale Ando's contributions to biotechnology and his innovative patents have made a significant impact in the field of genetic therapies. His work continues to inspire advancements that improve patient outcomes and enhance therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.